Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 June 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Valdecoxib Articles

Pharmacia suffers delay in USA for injectable COX-2 inhibitor parecoxib

16 July 2001

Pharmacia files for follow-up COX-2 OK

23 March 2001

Pharmacia fourth-quarter earnings jump 32%, driven by Celebrex sales

13 February 2001

Pfizer forecasts strong revenue growth in 2001-2002 at R&D meeting

14 December 2000

Merck & Co reiterates independence at pipeline presentation

14 December 2000

Pharmacia files NDA for first injectable COX-2 inhibitor, parecoxib

31 October 2000

US market growth of 16.9% driving world pharmaceutical sales, says IMS

18 October 2000

Pharmacia terminates leridistim program on disappointing results; good

26 July 2000

Pfizer and Warner-Lambert merger creates industry's largest R&D budget

10 February 2000

Interneuron crashes again as citicoline fails in stroke

13 January 2000

Interneuron surges on pagoclone license

29 December 1999

Yamanouchi watching Lipitor developments

24 November 1999

Pfizer reveals new products in bid to boost profile after hostile bid for

18 November 1999

Knoll and Incara end Bextra agreement

12 August 1999

Bextra trial terminated on interim data, no survival advantage

3 August 1999

Beta Blockers Show Further Value In Heart Failure

18 November 1998

Astra Pulls Out Of Bextra Collaboration

1 October 1998

Intercardia May Drop Astra As Bextra Partner

6 August 1998

Showing 101-118 of 118 articles

Go to beginningPrevious
  • 1
  • 2
NextGo to end
  • Hot Topics
  • Most Read
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform
  • Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
  • US Supreme Court says patent settlement can "sometimes" be illegal
  • Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
  • FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
  • Australia's pharma industry applauds R&D regulatory reform

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS